Previous reports indicated that NSCLC patients with MET exon 14 skipping mutation often possessed codriver alterations, such as EGFR amplification (6–28%), fibroblast growth factor receptor 1 (FGFR1) alterations (5–17%), KRAS alterations (~ 8%), BRAF alterations (~ 21%), and PIK3CA mutation/amplification (~ 14%) [11]. Here, MET is linked to non-small cell lung carcinoma.